GP-Leds

The law firm has been growing its PE funds team, which advised on 150 secondaries deals worth $17.5bn in 2019.

The listed firm brought the launch of Strategic Equity IV forward by two years due to faster-than-expected deployment.

This is at least the second appointment Goldman’s financial sponsors M&A group has made from Lazard after the appointment of MD Alex Mejia who will start in May.

The deals are increasingly seen as an alternative to exit and will drive activity in Asia-Pacific say Greenhill’s Briac Houtteville and Lloyd Bradbury.

A positive selection bias, deep due diligence and strong alignment make GP-led secondaries an attractive proposition, write managing directors Brian Mooney and Stephen Sloan in this sponsored Q&A.

The top-level hire will work with co-head Michael Woolhouse to build out the firm’s secondaries team, Secondaries Investor has learned.

The appetite for recapitalisations of small numbers of high-performing assets is adding opportunities (and challenges) to the GP-led market, say Travers Smith partner Sam Kay and senior associate Ed Ford.

The buyout shop is making a €300m investment from its latest fund in the process, which values Springer Nature at about $7bn.

Innovation should drive the continued growth of the GP-led secondaries market, write Nigel Dawn and Ryan Rohloff in this sponsored article.

The process is one of the largest in the market, rivalling that of New Mountain Capital, which is moving five assets out of its 2007 fund in what could be a $2bn or more transaction.